Table 2.
Clinical Characteristics of Patients with COVID-19 Infection and Acro-Ischemia (I)
| Clinical Characteristics | Atypical Raynaud Phenomenon (n=4) | Pseudo-Pernio (n=5) | Severe Microcirculatory Ischemia with Preserve Pulse (n=6) | Dry Gangrene with Arteriosclerosis Obliterans (n=9) |
|---|---|---|---|---|
| Type of patient | ||||
| Outpatients | 4 | 5 | 0 | 0 |
| Hospital: ward | 0 | 0 | 6 | 1 |
| Hospital: critical care | 0 | 0 | 0 | 8 |
| Covid-19 symptoms (%) | ||||
| Fever | 100 | 100 | 100 | 100 |
| Malaise | 100 | 100 | 100 | 100 |
| Cough | 100 | 100 | 100 | 100 |
| Diarrhea | 75 | 100 | 100 | 100 |
| Headache | 100 | 80 | 100 | 100 |
| Hyposmia | 50 | 0 | 50 | 55 |
| Dysgeusia | 50 | 40 | 50 | 67 |
| Others symptoms (%) | ||||
| Arthralgia | 25 | 40 | 50 | 55 |
| Loin pain | 50 | 0 | 0 | 0 |
| Otalgia | 25 | 0 | 0 | 0 |
| Lymphadenopathy | 25 | 20 | 0 | 0 |
| Genitalia (ulcer) | 25 | 0 | 0 | 0 |
| Viral pneumonia (%) | 0 | 0 | 100 | 100 |
| Disease severity (%) | ||||
| Mild | 100 | 100 | – | – |
| Moderate | – | – | 33 | – |
| Severe | – | – | 67 | 100 |
| CURB-65 score 2 (%) | 67 | 77 | ||
| SaO2/FiO2 | – | – | >140 | <140 |
| Covid-19 treatment (%) | ||||
| Hydroxychloroquine | – | – | 100 | 100 |
| Lopinavir/Ritonavir | – | – | 67 | 77 |
| Interferon | – | – | 50 | 77 |
| Glucocorticoids | – | – | 83 | 55 |
| Tocilizumab | – | – | – | 22 |
| Cyclosporine | – | – | – | 22 |
| Colchicine | – | – | – | 11 |
| LMWH before skin event (%) | ||||
| Prophylactic doses | – | – | 50 | 44 |
| Medium doses | – | – | 16,7 | 22 |
| High doses | – | – | 33 | 33 |
| Skin event treatment (%) | ||||
| Antiplatelet | 25 | 20 | 17 | 22 |
| Anticoagulant | 0 | 0 | 100 | 100 |
| Statin | 0 | 40 | 17 | 22 |